---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-254571"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:44:37.447140+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kyverna reports positive Phase 2 interim data for KYV-101 in gMG; 100% response rate

## Summary
- 100% (6/6) of patients achieved clinically meaningful reductions in MG-ADL and QMG at 24 weeks.
- Mean reductions of -8.0 points (MG-ADL) and -7.7 points (QMG) from baseline; responses seen as early as 2 weeks.
- No high-grade CRS or ICANS observed; one SAE of Grade 4 neutropenia resolved to Grade 1.
- All patients free of nonsteroidal immunosuppressants, high-dose steroids, FcRn, and complement inhibitors.
- Company plans to initiate Phase 3 portion of KYSA-6 trial by end of 2025.

## SEC filing metadata
- accession: 0001193125-25-254571
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312525254571/0001193125-25-254571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312525254571/d80007d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-254571
- JSON: https://secwatch.observer/filing/0001193125-25-254571.json
- Plain text: https://secwatch.observer/filing/0001193125-25-254571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.